Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.42 |
| ▸ | CNR2 | P34972 | 3/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 6/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3006934 | 0.93 | CTSS (0.42) | CTSSCNR2NPSR1MAPTSMN1; SMN2 | |
| SCHEMBL3010412 | 0.91 | CTSS (0.41) | CTSSPTGER1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL3016558 | 0.90 | CTSS (0.42) | CTSSSMN1; SMN2RAB9AAURKAAURKB | |
| SCHEMBL3018021 | 0.89 | CTSS (0.41) | CTSSSMN1; SMN2RAB9AAURKAAURKB | |
| SCHEMBL3018933 | 0.89 | CTSS (0.42) | CTSSSMN1; SMN2NPC1RAB9AAURKA | |
| SCHEMBL3005413 | 0.89 | CTSS (0.44) | CTSSMAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL2998477 | 0.88 | CTSS (0.44) | CTSSSMN1; SMN2NPC1RAB9AAURKA | |
| SCHEMBL3008961 | 0.87 | TDP1 (0.41) | PTGER1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL3004540 | 0.86 | CNR2 (0.40) | CNR2NPSR1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL3009850 | 0.86 | CNR2 (0.41) | CTSSCNR2MAPTSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722681-B2 | N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases | NV REMYND (BE) | 2014-05-13 | — | — | US | disclosed |
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | SMN1; SMN2, HTT, SNCA | CTSS 106/4885CNR2 2911/4885PTGER1 3900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.